应用顺铂时辰化疗治疗晚期非小细胞肺癌的疗效观察  

Clinical Trial of Cisplatin-based Chronotherapy for Advanced None-small Cell Lung Cancer

作　　者：李洁[1,2] 季枚[3] 朱丽娜[3] 邹素兰[1] 王友群[2] 

机构地区：[1]江苏常州市第一人民医院药剂科,常州市213000 [2]中国药科大学药学院,南京市210009 [3]江苏常州市第一人民医院肿瘤科,常州市213000

出　　处：《中国药房》2010年第44期4171-4173,共3页China Pharmacy

摘　　要：目的:观察应用顺铂时辰化疗在晚期非小细胞肺癌治疗中的临床疗效。方法:选择晚期非小细胞肺癌患者29例,根据最小化随机法分时辰化疗组(n=13)和常规化疗组(n=16),考察2组临床疗效和毒副反应的差异。结果:时辰化疗组有效率为53.85%,常规化疗组为43.75%,2组间差异无统计学意义(P>0.05)。严重白细胞下降(Ⅲ级+Ⅳ级)者,时辰化疗组为7.69%(1/13),常规化疗组为43.75%(7/16);严重中性粒细胞下降(Ⅲ级+Ⅳ级)者,时辰化疗组为15.38%(2/13),常规化疗组为62.5%(10/16);消化道毒性反应(恶心)发生者,时辰化疗组为15.38%(2/13),常规化疗组为62.5%(10/16),差异均有统计学意义(P<0.05)。结论:以顺铂为基础的时辰化疗治疗晚期非小细胞肺癌在减轻毒副反应方面有一定的优势,有进一步研究的价值。OBJECTIVE：To evaluate the superiority of cisplatin-based chronotherapy in the treatment of advanced none-small cell lung cancer（NSCLC）.METHODS：29 patients with advanced NSCLC were divided into chronotherapy group and routine chemotherapy group.The clinical efficacy and toxicity were investigated and compared between 2 groups.RESULTS：There is no significant in total response rate between chronotherapy group（53.85%）and routine chemotherapy group（43.75%）.The rate of leucopenia（grade Ⅲ or Ⅳ）was 7.69% in chronochemotherapy group and 43.75% in routine chemotherapy.The rate of neutropenia（grade Ⅲ or Ⅳ）was 15.38% in chronochemotherapy group and 62.5% in routine chemotherapy group.The rate of gastrointestinal toxicity（nausea）was 15.38% in chronochemotherapy group and 62.5% in routine chemotherapy group,there was statistical significance（P〈0.05）.CONCLUSION：Cisplatin-based chemotherapy has advantage in relieving side effects of chemotherapy,and more clinical researches are needed.

关 键 词：时辰化疗 顺铂 晚期非小细胞肺癌 

分 类 号：R473.73[医药卫生—护理学]